Reported 1 day ago
President-elect Donald Trump has threatened to impose higher tariffs on Denmark due to its control of Greenland, which could significantly affect the Danish pharmaceutical giant Novo Nordisk. As a key player in the U.S. pharmaceuticals market, especially in GLP-1 weight-loss drugs, Novo Nordisk stands to suffer if such tariffs are enacted. Trump's potential use of the International Economic Emergency Powers Act to introduce these tariffs has prompted speculation on the advantages this could bring to American competitors like Eli Lilly.
Source: YAHOO